23
Jun
National Priority Vouchers to Companies - Lachman Blog 2

More on the Commissioner’s National Priority Vouchers to Companies Supporting U.S. National Interests

The FDA issued a News Release (here) that provides some additional information about the program. “‘Using a common-sense approach, the national priority review program will allow companies to submit the lion’s share of the drug application before a clinical trial is complete so that we can reduce inefficiencies. The ultimate goal is to bring more […]

Read More
23
Jun
Symbol of scales

Revised Q1 Draft Stability Document Issued by FDA

The newly revised and expanded draft guidance titled Q1 Stability Testing of Drug Substances and Drug Products (here) was published today.  This draft guidance represents “a consolidated revision of the ICH Q1A(R2), Q1B, Q1C, Q1D, Q1E, and Q5C series of stability guidances, published November 2003, March 1996, May 1997, January 2003, June 2004, and July […]

Read More
20
Jun
The National Priority Voucher - Lachman Blog

Faster Drug Approvals Under New Program – The National Priority Voucher

An Associated Press article (here) reported that “Food and Drug Administration Commissioner Marty Makary said the agency will aim to review select drugs in one to two months.” This would be accomplished by a team of reviewers similar to those formed under Operation Warp Speed for approvals of the COVID-19 vaccines. “Makary said he will […]

Read More
12
Jun
Red apple with bite

Another Bite at the Apple!

Yesterday, U.S. Senators Markwayne Mullin (R-OK) and Cory Booker (D-NJ) reintroduced the “Prescription Information Modernization Act of 2025.”  You’ll likely remember that it has had quite a history.  It’s a commonsense bill that would allow firms to use electronic labeling, eliminating the requirement to include paper package inserts, better known as the prescribing information, while […]

Read More
03
Jun
Do More with Less - Lachman Blog

Do More with Less – Looks Like That Is What the FDA Budget Request Asks

Now, here is a head scratcher. According to the Pink Sheet article written by Sue Sutter (here), “The White House requested $6.76bn, a decrease of 3.9%, or $271.5m, from the FY 2025 funding level. The proposal includes $3.17bn in budget authority, a decrease of 11.4%, and $3.59bn in user fees, a 4% increase.” What a dandy, […]

Read More
02
Jun
Some Policy Staff Returning to CDER Now - Lachman Blog

Some Policy Staff Returning to CDER Now

According to an article in the Pink Sheet (here, subscription required) authored by Sarah Karlin-Smith, some policy staff are returning to work at the Center for Drug Evaluation and Research. Hopefully that means that we will see more timely work on product-specific guidances (PSGs), informational postings, and statistical reporting from the Agency. In the Office […]

Read More
30
May
Color Additive Changes in a Drug Product – Regulatory Relief is on the Way - Lachman Blog

Color Additive Changes in a Drug Product – Regulatory Relief is on the Way

Yesterday, the FDA issued a draft guidance titled “Replacing Color Additives in Approved or Marketed Drug Products” (here). We all know that removing or partially removing a color from a product was an easy annual reportable change, and this remains unchanged in the draft guidance. However, changing a color by replacing it with another color […]

Read More
20
May
Close up of man having itch caused of a red rash

Scratch My Itch

The FDA warns about the potential for rare but severe itching after discontinuation of cetirizine or levocetirizine for both over-the-counter (OTC) and prescription drug products (here).  The FDA says, ”[t]he itching, also called pruritus, has been reported in patients who used these medicines daily, typically for at least a few months and often for years. […]

Read More
12
May
US Food and Drug Administration (FDA)

Priority Review Vouchers a Hot Commodity

Over the last eight months, a number of priority vouchers were sold by firms that were subject to the award of either a tropical disease priority review voucher, a rare pediatric disease priority review voucher, or a material threat medical countermeasure (MCM) priority review voucher.  The purchase prices of these vouchers, while not as high […]

Read More
1 … 7 8 9 … 35